CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 1  
 
 
Healthcare Worker Exposure Response and Outcomes of 
Hydroxychloroquine Trial (HERO -HCQ Trial)  
 
 
 
 
Protocol Number:  
 COVID -19-2020 -001 
 
IND Number:  
 149266  
Principal 
Investigator /IND 
Sponsor : Adrian Hernandez, MD  
Duke Clinical Research Institute  
[ADDRESS_553538].  
Durham, NC [ZIP_CODE]  
Phone: 919 -668-7515  
Email: [EMAIL_1789]  
Co-Principal 
Investigator  [INVESTIGATOR_436909], MD  
Duke Clinical Research Institute  
[ADDRESS_553539].  
Durham, NC [ZIP_CODE]  
Phone: 919 -684-2584  
Email: [EMAIL_1790]  
Data Coordinating 
Center Investigator  Kevin Anstrom, PhD  
Duke Clinical Research Institute  
[ADDRESS_553540].  
Durham, NC [ZIP_CODE]  
Phone: 919 -668-8902  
Email: [EMAIL_2399]  
Lead   
Funding Agency:  
 Patient -Centered Outcomes Research Institute  
Version:  
 3.0 
Date:  7/07/2020 
 
 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 2 Statement of Compliance  
 
This trial will be conducted  in compliance with the  International Council for Harmonisation 
(ICH) E6(R2) guideline for Good Clinical Practice (GCP), and the applicable regulatory 
requirements from the [LOCATION_002] Code of Federal Regulations (CFR), including  45 CFR 46 
(Human Subjects Protection); 21 CFR 3 12 (Investigational New Drug) ; 21 CFR  50 (Informed 
Consent), and 21 CFR 56 (Institutional Review Board [IRB]).  
All individuals who are responsible for the conduct, management, or oversight of this study have 
completed Human Subjects Protection and ICH GCP  Training.  
 
 
  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553541] read the protocol, including all appendices, and the package insert/product label, and I 
agree that the protocol contains all necessary details for my staff and me to conduct this study as 
described. I will personally oversee the conduct of this study as outlined herein and will make a 
reasonable effort to complete the study within the time designated. I agree to make all reasonable 
efforts to adhere to the attached protocol.  
I will provide all study personnel under my supervision with copi[INVESTIGATOR_88472]’s representative.  I will discuss this 
material with study personnel to ensure that they are fully informed about the e fficacy and safety 
parameters and the conduct of the study in general. I am aware that, be fore beginning this study, 
the Institutional Review Board (IRB),  or equivalent oversite entity  must approve this protocol in 
the clinical facility where it will be co nducted.  
I agree to obtain informed consent from participants , as required by [CONTACT_88526] I CH guidelines. I further agree to report to the sponsor 
or its representative any adverse events in accordance with  the terms of this protocol and the U.S. 
Code of Federal Regulations, Title 21, part 312.64, ICH GCP 4.11. I further agree to ensure the 
study is conducted in accordance with the provisions as stated and will comply with the 
prevailing local laws and custo ms. 
 
 
   
Site Principal Investigator [CONTACT_5627] (Print)   
   
   
Site Principal Investigator [INVESTIGATOR_436910] -HCQ Protocol [v3.0]  
 
 4 Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ ........ 11 
1.1. Synopsis  ................................ ................................ ................................ .......................... 11 
1.2. Schema  ................................ ................................ ................................ ............................ 13 
2. Introduction  ................................ ................................ ................................ ................... 14 
2.1. Study Rationale  ................................ ................................ ................................ ............... 14 
2.2. Background  ................................ ................................ ................................ ..................... 14 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 15 
2.3.1. Risk Assessment  ................................ ................................ ................................ ............. 15 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ ......... 16 
3. Objectives and Endpoints  ................................ ................................ ............................ 17 
4. Study Design  ................................ ................................ ................................ .................. 18 
4.1. Overall Desig n ................................ ................................ ................................ ................ 18 
4.2. End of Study Definition  ................................ ................................ ................................ ..18 
5. Study Population  ................................ ................................ ................................ ........... 19 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 19 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 19 
5.3. Recru itment and Engagement  ................................ ................................ ......................... 20 
5.3.1.  Participant Recruitment  ................................ ................................ ................................ ..20 
5.3.2.  Participant Engagement  ................................ ................................ ................................ ..20 
5.3.3.  Participant Randomization Process ................................ ................................ ................. 20 
5.4. Screen Failures  ................................ ................................ ................................ ................ 21 
6. Study Drug(s)  ................................ ................................ ................................ ................ 22 
6.1. Hydroxychloroquine  ................................ ................................ ................................ .......22 
6.1.1.  Formulation, Appearance, Packaging, and Labeling  ................................ ...................... 22 
6.1.2.  Drug Dispensing, Storage, and Stability  ................................ ................................ ......... 22 
6.1.3.  Dosing and Administration  ................................ ................................ ............................. 22 
6.1.4.  Rationale for Selection of Dose  ................................ ................................ ...................... 22 
6.2. Placebo  ................................ ................................ ................................ ............................ 23 
6.2.1.  Formulation, Appearance, Packaging, and Labeling  ................................ ...................... 23 
6.2.2.  Drug Dispensing, Storage, and Stability  ................................ ................................ ......... 23 
6.2.3.  Dosing and Administration  ................................ ................................ ............................. 23 
6.2.4.  Rationale for Selection of Dose  ................................ ................................ ...................... 23 
6.3. Study Drug Accountability  ................................ ................................ ............................. 23 
6.4. Concomitant Therapy  ................................ ................................ ................................ .....24 
6.5. Dose Modification  ................................ ................................ ................................ .......... 24 
6.6. Intervention After the End of the Study ................................ ................................ .......... 25 
7. Participant Withdrawal/Termination and St udy Termination  ................................ 26 
7.1. Participant Withdrawal/Termination  ................................ ................................ .............. [ADDRESS_553542] to Follow -up................................ ................................ ................................ ............ 26 
8. Study Assessments and Procedures ................................ ................................ ............. 28 
8.1. Schedule of Events ................................ ................................ ................................ .......... 28 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 5 8.1.1.  Baseline (On -site, Day 0)  ................................ ................................ ................................ 29 
8.1.2.  Follow -Up ................................ ................................ ................................ ....................... 29 
8.1.3.  Final Visit (Day 60 + 5 days - Remote)  ................................ ................................ .......... 30 
8.2. Clinical Assessments  ................................ ................................ ................................ ......30 
8.3. Quality of Life and COVID Questionnaires  ................................ ................................ ...30 
9. Safety Assessments  ................................ ................................ ................................ ........ 32 
9.1. Adverse Events and Serious Adverse Events  ................................ ................................ .32 
9.1.1.  Collection Period for AE and SAE Informat ion ................................ ............................. 32 
9.1.2.  Assessing Causality of a Suspected Unexpected Serious Adverse 
Reaction (S[LOCATION_003]R)  ................................ ................................ ................................ .......... [ADDRESS_553543] ................................ ................................ ................................ 33 
9.2. Unanticipated Problem (UP) and Terminations ................................ .............................. 34 
9.2.1.  Definition of Unanticipated Problem  ................................ ................................ .............. 34 
9.2.2.  Reporting of an Unanticipated Problem  ................................ ................................ ......... 35 
10. Statistical Considerations  ................................ ................................ ............................. 36 
10.1.  Statistical Hypotheses  ................................ ................................ ................................ .....36 
10.1.1. Primary Hypothesis  ................................ ................................ ................................ ......... 36 
10.1.2.  Secondary Hypotheses  ................................ ................................ ................................ ....36 
10.2.  Sample Size Determination  ................................ ................................ ............................ 36 
10.3. Randomization  ................................ ................................ ................................ ................ 36 
10.4.  Blinding  ................................ ................................ ................................ .......................... 36 
10.5.  Populations for Analyses  ................................ ................................ ................................ 37 
10.6.  Statistical Analyses  ................................ ................................ ................................ ......... 37 
10.6.1.  General Considerations  ................................ ................................ ................................ ...37 
10.6.2.  Primary Endpoint  ................................ ................................ ................................ ............ 37 
10.6.3.  Secondary Endpoint(s)  ................................ ................................ ................................ ....[ADDRESS_553544] (DSMB)  ................................ ................................ ......... [ADDRESS_553545] (IRB)  ................................ ................................ ................... [ADDRESS_553546] Keepi[INVESTIGATOR_007]  ................................ ................................ ........... 44 
12.1.  Data Collection and Management Responsibilities  ................................ ........................ 44 
12.2.  Study Records Retention  ................................ ................................ ................................ 45 
12.3.  Protocol Deviations ................................ ................................ ................................ ......... 45 
12.4.  Publication and Data Sharing Policy  ................................ ................................ .............. 46 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 6 13. Study Leadership  ................................ ................................ ................................ .......... 47 
14. Summary of Changes ................................ ................................ ................................ ....48 
15. References  ................................ ................................ ................................ ...................... 52 
 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553547]  
ICF Informed Consent Form  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553548]  
MBI  Maslach Burnout Inventory  
MOI  Multiplicity on Infection  
MOP  Manual of Procedures  
NIH National Institute of Health  
OHRP  Office for Human Research Protections  
PHI Personal Health Information  
PHQ  Patient Health Questionnaire  
PROMIS  Patient -reported Outcomes Measurement Information System  
QoL Quality of Life  
SAE  Serious Adverse Event  
S[LOCATION_003]R  Serious Unexpected Suspected Adverse Reaction  
UP Unanticipated Problems  
  
 
 
 
 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 9 Table of Figures  
Figure 1: Data Flow Diagram  ................................ ................................ ................................ ....... 44 
Figure 2: Operational Structure Diagram  ................................ ................................ .....................  47 
 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553549] of Table s 
Table 1: Schedule of Events  ................................ ................................ ................................ .........  28 
 
 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 11 1. Protocol Summary  
1.1. Synopsis  
 
Title  Healthcare Worker Exposure Response and Outcomes of 
Hydroxychloroquine  Trial ( HERO -HCQ Trial ) 
Clinical study phase  III 
Rationale  Severe acute respi[INVESTIGATOR_6507] [ADDRESS_553550] isolated in January 2020 and has since caused a global 
pandemic unseen in decades in cases and mortality. [1, 2]  At the 
time of initial protocol submission in April 2020, h uman vaccine 
clinical trials ha d just begun  and experts predict ed that a vaccine 
would not be available until April [ADDRESS_553551] , therefore  
new measures remain  desperately needed to prevent the spread of 
disease. [3] In vitro  studies suggest a potential moderate antiviral 
effect of  hydroxychloroquine (HCQ) and its well known safety 
profile and oral formulation make it an ideal drug candidate for 
prevention.  
Primary Objective   To evaluate the efficacy of HCQ  to prevent COVID -19 clinical 
infec tion in healthcare workers (HCW s)  
Secondary 
Objectives   To evaluate the efficacy of HCQ to prevent viral shedding of 
SARS -CoV -2 among HCWs  
 Evaluate  safety  and tolerability  of HCQ  
Exploratory 
Objectives   Evaluate  SARS -CoV -2 seroconversion in participants taking 
HCQ  
 Describe COVID -19 infectious complications in participants 
taking HCQ  
 Describe time off from work for medical reasons in 
participants taking HCQ  
 Describe Quality of Life (QoL)  
 Describe experience  of house hold contacts 
Intervention  Treatment Group: Hydroxychloroquine 600  mg BID (two times 
a day) loading dose  for 1 day,  followed by 400  mg QD  (once a 
day) for 29 days  
Control Group: placebo  
Study Design  Eligible participants will be randomized (1:1) , stratified by [CONTACT_3725], 
in a blinded fashion to either the treatment group  (HCQ)  or 
placebo .  Participants will receive a 30 -day supply of study drug 
or placebo, depending on randomiz ation arm .  There will be  two 
on-site visits and four remote visits over an approximately 60 
day period during which participants  will complete various QoL 
questionnaires, provide serum samples, and undergo COVID -19 
testing.    
Population  Approximately 2,000 adult HCW s   
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 12 Study Duration  12 months  
Study Location  Approximately 40 US PCORnet sites  
Key Inclusion 
Criteria   Healthcare worker age  >18 years old  
 Currently working in any environment in which there is a risk of  
exposure  to patients with COVID -19 infections (“healthcare 
worker”)    
Key Exclusion 
Criteria   Prior diagnos is of COVID -19 infection  
 Respi[INVESTIGATOR_436911] -onset fever (Temperature > 10 0°F) 
or ongoing cough or dyspnea within 14 days 
 Congenital prolonged QT syndrome  
 Current or planned use of QT prolonging drugs  (see Section 
5.2) and other contraindicated medications  
 End stage renal disease  
 Current or planned use of the following for treatment or 
prevention of COVID -19 infection:  
o Hydroxychloroquine (study drug) or chl oroquine  
o Azithromycin  
 Ventricular arrhythmias requiring medical treatment  
 Severe coronary artery disease or heart failure/cardiomyopathy 
with ongoing symptoms  
Sample S ize 
Considerations  A sample size of approximately 2,000 randomized participants is 
expected to provide 80% power to detect a  relative 50% 
reduction in the risk of clinical infection with COVID -19 
assuming a control group risk of 5%.   
Statistical Analysis 
Plan for Primary 
Objective  The primary objective wi ll be assessed by [CONTACT_436922] -19 at the end of the treatment period .  For 
the clinical infection with COVID -19 endpoint, a comparison of 
treatment and control group s will be conducted using a Fisher’s 
exact test. The primary m easure of treatment effect will be based on 
a difference in proportions with the associated 95% confidence 
interval. A secondary analysis will be performed using a logistic 
regression model.   
Data Safety 
Monitoring Board 
(DSMB )  Frequent  DSMB reviews will  be conducted to ensure the safety of 
study participants and evaluate the accumulating endpoint data by 
[CONTACT_1570]. Regular DSMB meetings will monitor the 
following parameters at a minimum:  
 Recruitment progress  
 Enrollment overall and by [CONTACT_12125]  
 Adhe rence, retention, and status of data collection  
 Serious adverse events  
Interim Analysis  Given the rapid spread of COVID -19, it is expected that reviews of 
the study data will occur approximately weekly following the 
enrollment of the first participants. Formal interim reviews for 
efficacy will be based on the accrual of primary endpoint data.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 13 1.2. Schema  
 
 

CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 14 2. Introduction  
2.1. Study Rationale  
Severe acute respi[INVESTIGATOR_6507] 2  (SARS -CoV -2) is a novel betacoronavirus first 
isolated in January [ADDRESS_553552] 
to the number of cases and overall mortality. [1, 2]  The clinical disease related to  SARS -CoV -[ADDRESS_553553] 
that a vaccine will not be available for 12 -18 months, and new measures are desperately needed 
to prevent the spread of disease.  [3] In vitro  studies suggest a potential moderate antiviral effect 
of  hydroxychloroquine (HCQ) and its well known safety profile and oral formulation make it an 
ideal drug candidate for prevention.    
2.2. Background  
In December  2019,  numerous patients in Wuhan, China were diagnosed with pneumonia caused 
by [CONTACT_88529]. By [CONTACT_36466] 7, 2020,  Chinese scientists had isolated SARS -CoV -2. This is 
a novel betacoronavirus closely related to severe acute respi[INVESTIGATOR_6507]  (SARS -
CoV -1). [2]  In the subsequent months the spread of the virus led to  a global pandemic. As of 
March 31, 2020,  there were approximately  803,313  confirmed  COVID -19 cases resulting in  
39,014 deaths worldwide. [1] 
Healthcare workers have been disprop ortionately affected by [CONTACT_436923]. Over 3,[ADDRESS_553554] become 
infected, accounting for 14% of the country’s total infections. In Brescia, the center of Italy’s 
outbreak , 10-15% of doctors and nurses have been infected and are unable to work.  [4] In 
addition to potential exposure to infected patients, a critical shortage of personal protec tive 
equipment and respi[INVESTIGATOR_436912]. [5] 
The virus continues to spread despi[INVESTIGATOR_88480]. Human 
vaccine clinical trials have just begun, but experts predict  that a vaccine will not be available for 
12-18 months, and new measures are desperately needed to prevent the spread of disease. [3] 
As of  July 2020,  multiple clinical trials have completed providing early guidance to clinical 
providers on management of COVID -19, particularly in the hospi[INVESTIGATOR_6885]. Two therapi[INVESTIGATOR_014], one 
investigational (remdesivir) and one that has been FDA approved for years  (dexamethasone), 
have been reported to improve clinical disease and in the case of dexamethasone, mortality . [6, 
7] Numerous medications are currently under investigation including additional studies of 
remdes ivir, lopi[INVESTIGATOR_054]/ ritonavir, chloroquine, HCQ , and numerous immunomodulatory agents. No 
therapi[INVESTIGATOR_88483] - or post -exposure prophylaxis and clinical  trials are 
currently underway. [8, 9]  While the large RECOVERY trial has reported results from the HCQ  
arm and report no benefit from HCQ for therapy in the hospi[INVESTIGATOR_6885], it remains u nclear if there 
is a benefit from HCQ in the setting of pre - or post -exposure prophylaxis.  
In February  [ADDRESS_553555] SAR S-CoV -2 at low micromolar concentrations.  This was consiste nt with prior data 
illustrating chloroquine’s activity against SARS -CoV -1 and MERS -CoV. [10] Liu et al and Yao 
et al have similarly reported micromolar concentration EC50 for hydroxychloroquine on SARS -
CoV -2. [11, 12]  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 15 Both Chloroquine and HCQ  are alkalinizing lysosomatrophic drugs th at accumulate in 
lysosomes and block viral infection by [CONTACT_436924], which is required for the 
virus/cell fusion. Coronavirus infectivity is extremely sensitive to pH, and increasing the pH 
inhibits virus/cell fusion. [13] They also interfere with the glycosylation of the cellular receptors 
of coronaviruses, including SARS -CoV -2. One of the benefit of  chloroquine and HCQ  function 
at both entry and post -entry stages of the infection.  [10]  
In addition to the potential antiviral effect, hyd roxychloroquine is a well-recognized  
immunomodulatory agent, currently used as a disease -modifying agent in autoimmune diseases 
including systemic lupus erythematosus . Use may  prevent the severity of  COVID -19 or attenuate 
the development of immune -mediated  complications such as acute resp iratory distress syndrome 
(ARDS ). [14] ARDS is a potentially severe complication of COVID -19 infection. In the study of 
138 patients  in Wuhan , ARDS developed in 20 percent after a median of e ight days, and 
mechanical ventilation was implemented in 12.3 percent.  [15] In another study of 201 
hospi[INVESTIGATOR_41374] -19 in Wuhan, 41 percent developed ARDS . Of note,  age 
greate r than 65 years, diabetes mellitus, and hypertension were all associated with  development 
of ARDS . [16] 
Hydroxychloroquin e has similar activity to chloroquine in prior studies examining its efficacy in 
treatment of MERS and SARS. It has a better  safety and tolera bility profile  than chloroquine.  [8] 
It has already been FDA approved for malaria prophylaxi s and treatment of various autoimmune 
conditions including rheumatoid arthritis and lupus. It can be dosed orally in a once daily 
formulation, which would be ideal for prophylaxis. It has a long serum half -life and, if effective, 
protection should last bey ond cessation of prophylaxis.  
2.3. Benefit/Risk Assessment  
The risks for participation in this study  include  taking study drug , phlebotomy blood draws , and 
nasopharyngeal swabs. The safety of HCQ  is well known and the risk of taking the drug is 
particularly low given the short cou rse of therapy.   There may be some benefit to th e participant 
if the prophylactic  therapy is effective and prevents transmission of infection and/or clinical  
disease.  
2.3.1.  Risk Assessment  
Blood draw risks : Risks associated with drawing blood include momentary discomfort and/or 
bruising. Infection, excess bleeding, clotting, or fainting are also possible, although unlikely.  
Nasopharyngeal swab risks : Risks include mild irritatio n, insignificant local pain, and minor 
bleeding.  
Hydroxychloroquine risks : Hydroxychloroquine has been used clinically for years as a 
prophylactic and treatment for malaria, and in the [LOCATION_002] more broadly for autoimmune 
conditions. The primary toxicity concerns include retinopathy, QTc prolongation, nausea, rash 
and bone marrow suppression. While toxicity is more common with long -term use as done for 
autoimmune conditions , it’s prudent to consider thes e risks .  Risks of HCQ include:  
 Retinopathy:  The recommended maximum dose to limit toxicity is 5 mg/kg actual body 
weight per day. The retinopathy risks increases once the total exposure is >1000 g. The 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 16 proposed dose of 600  mg BID on day 1 followed by 400  mg QD for 29 days does not 
exceed 20 g. Due to the finite therapy and the low total exposure, the risk fo r retinopathy 
is low and thus does not warrant a baseline eye exam.   
 QTc prolongation: QTc prolongation is a risk for chloroquine and thus may be a risk for 
HCQ , although the risk is believed to be lower. The risk of QTc prolongation is more 
likely an issue for HCQ  when dosed with other concomitant medications that prolong 
QTc. For this reason , concomitant medications with high risk for QTc prolongation will 
be excluded as will congenital QTc prol ongation syndromes.  
 Allergic rash:  In approximately 1 -5% of patients , an allergic rash  develops.  This pruritic 
eruption usually occurs after 1 -2 weeks of dosing. Guidance will be provi ded to teams for 
managing allergic rash.  
 Nausea /diarrhea : Gastrointesti nal symptoms may occur  with higher doses and sometimes 
with daily dosing of HCQ . Dividing daily dosing BID or TID is a commonly used 
strategy to improve tolerance. Guidance will be provided to teams for managing nausea  
and diarrhea . 
 Severe hypoglycemia inc luding loss of consciousness that could be life threatening has 
been reported in patients treated with or without antidiabetic medications.   
 Neuropsychiatric events, including suicidal behavior have been reported.  
 Other potential toxicities including bone  marrow suppression, arrhythmia , and 
hypoglycemia .  These  are not likely  with a finite  course of  therapy. Furthermore, there is 
no evidence that G6PD deficiency is a problem with HCQ . While different class of 
antimalarial  causes hemolysis with G6PD deficiency, there are no reports of hemolysis 
with HCQ .  
Risk lowering measures : Study procedures to manage and minimize risks include careful 
selection of the participants and monitoring over time to check on participants ’ health. 
Additional guidance to manage any risks will be provided to the study teams, as needed.  In 
addition, an independent DSMB will monitor safety of the participants throughout the study.  
2.3.2.  Benefit Assessment  
Participants who randomize to the treatment group  may benefit from the prophylactic study drug 
administration.  There is no direct benefit to participants randomized to the control group apart 
from participating i n generating evidence that may ultimately support preventative therapy for 
SARS -CoV -[ADDRESS_553556] profile of HCQ  in 
HCWs  will also inform the public taking HCQ for prophylaxis of SARS -CoV -2 infection and 
potentially treatment of COVID -19. 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 17 3. Objectives  and Endpoints  
Objectives  Endpoints  
Primary   
 To evaluate the efficacy of HCQ  to 
prevent COVID -19 clinical in fection in 
HCWs   Clinical infection with COVID -19: 
o Confirmed :  new-onset of fever  or 
cough or  dyspnea  AND  confirmed 
COVID -[ADDRESS_553557] result  via 
local PCR testing , OR 
o Suspected :  new-onset fever  or 
cough or dyspnea without local 
PCR testing due to local 
restrictions  and/or testing policies  
Secondary   
 To evaluate the efficacy of HCQ to 
prevent viral shedding of SARS -CoV -2 
among HCWs  
 Evaluate  safety  and tolerability  of HCQ   Viral shedding of SARS -CoV -2:  
o Central lab confirmed COVID -[ADDRESS_553558] 
 Safety and tolerability  as determined by 
[CONTACT_436925] ( SAEs ) 
and HCQ -associated Events of S pecial 
Interest (Section 9.1.4 ) 
Exploratory   
 Evaluate  SARS -CoV -2 seroconversion in 
participants taking HCQ  
 Describe COVID -19 infectious 
complications in participants taking HCQ  
 
 Describe time off from work  for medical 
reasons  in participants taking HCQ  
 Describe QoL 
 
 
 
 
 
 Describe experience of household 
contacts   Seroconversion at 1 month  
 
 COVID -19 complications : 
o hospi[INVESTIGATOR_059]  
o ICU level care or ventilation  
 Days sick or lost work -time 
 
 Patient -Reported Outcomes Measurement 
Information System  (PROMIS) Emotional 
Distress -Anxiety -Short Form, a Single 
Item Burnout Measure, Patient Health 
Questionnaire (PHQ -2) 
 
 Patient -reported clinical infections among 
household contacts and other impacts on 
household  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553559] in trial participation in th e HERO Registry and work at one of 
the 40 U.S. sites participating in this trial will be approached for participation in the HERO -HCQ 
trial.  Please refer to Section 5.3 for more details about the recruitment and informed consent 
process.   Approximately 2,000 HCWs from 40 U.S. sites will be en rolled i n this trial and 
followed for ~60 days.  
 
Eligible participants will be  randomly assign ed (1:1) , stratified by [CONTACT_3725],  to either treatment group 
(HCQ) or placebo  in a double -blind fashion .  After enrollment, baseline assessments will include 
nasopharyngeal swab for COVID -[ADDRESS_553560] to participant 
portal .  A call  center will provide support for any missed visits.  Follow -up includes  screening 
for COVID -19 clinical signs and/or symptoms , other respi[INVESTIGATOR_18073], non-infectious 
clinical events , adverse events , and QoL assessments .  For more details regarding follow -up 
procedures, please refer to Section  8.1.[ADDRESS_553561] completed the study if he/she has completed the Final Visit  at 
[ADDRESS_553562] participant in the study .  
Data from interim analyses or recommendations  by [CONTACT_436926].   
 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 19 5. Study Population  
All Eligibility Criteria will be obtained per participant.   
5.1. Inclusion Criteria  
1. Completed Informed Consent  
2. Age ≥ 18 years old  
3. Currently working in any environment in which there is a risk of exposure to patient s 
with COVID -19 infections (“healthcare worker”) including , but not limited to , the 
following example work exposures:  
a. in the Intensive Care Unit (ICU) , or 
b. in the Emergency department, or 
c. in Emergency services,  or 
d. in a COVID -19 hospi[INVESTIGATOR_5120]/ward, or 
e. in respi[INVESTIGATOR_297720] , or 
f. in COVID -19 testing location , or 
g. in a clinical or research laboratory handling COV ID-19 patient samples, or 
h. in inpatient hospi[INVESTIGATOR_436913] t/area , or 
i. in long-term care, assisted living  or skilled nursing facilities , or 
j. in outpatient care , or 
k. in dental offices , or 
l. in home health care , or 
m. in health services  for incarcerated populations , or 
n. in dialysis centers . 
5.2. Exclusion Criteria   
1. Prior diagnos is of COVID -19 infection  
2. Participation in another COVID -19 prophylaxis trial within 30 days of consent  
3. Respi[INVESTIGATOR_436911] -onset fever (Temperature > 10 0°F) or ongoing cough or 
dyspnea within 14 days 
4. Known allergy to HCQ or chloroquine  
5. Congenital prolonged QT syndrome  
6. Current or planned use of QT prolonging drugs (e.g. procainamide, disopyramide, 
mexil etine, flecainide, propafenone , amiodarone, sotalol, cimetidine, dronedarone , 
dofetilide , levofloxacin, ciprofloxacin, moxifloxacin ) and other contraindicated 
medications  [see Manual of Procedures ( MOP ) for full list of contraindicated 
medications]  
7. End stage renal disease  
8. Pre-existing retinopathy  
9. Current or planned use of HCQ (study drug) for any indication  
10. Current or planned use of the following  for treatment or prevention of COVID -19 
infection : 
a. Chloroquine  
b. Azithromycin  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 20 11. Known c irrhosis  or severe liver disease  
12. History of severe skin reactions such as Steven -Johnson syndrome, toxic epi[INVESTIGATOR_7387]  
13. History of psoriasis or porphyria  
14. Ventricular arrhythmias requiring medical treatment  
15. Severe coronary artery disease or heart failure/cardiomyopathy with ongoing symptoms  
16. Current or planned use of use of anti -seizure  drugs  
17. History of Glucose -6-phosphate dehydrogenase deficiency  
5.3. Recruitment and Engagement  
5.3.1.  Participant Recruitment  
To ensure HERO -HCQ  accrues and retains the number and diversity of participants required to 
assess the primary and secondary endpoints, the HERO Registry  will be used to facilliate 
participant recruitment .  Sites may also  recruit directly from  their communities , with onboarding 
facilitated through the HERO  Registry . 
IRB-approved materials will be available on the HERO study website, including videos with 
English or Spanish subtitles, frequently asked questions (FAQs), and testimonials from 
participants. Potential participants who would like to learn more about the study will be directed 
to the study call center or the study website.  
The HERO registry will be used to pre -screen potential HCWs for this study.  Registry 
leader ship will periodically review the list of registry participants to identify potential 
participants  and ensure methods are used to populate the trial to achieve the objectives as well as 
diversity . Participants who appear to be eligible based on demographic s (including geographic 
region), clinical characteristics, and interest in being contact[CONTACT_436927] -HCQ clinical trial. The 
email  invitation will contain i nstructions for contact[CONTACT_436928].  
5.3.2.  Participant Engagement  
Participants will be engaged in the study  through  multiple channels.  This includes , but is not 
limited to , ongoing participation in the HERO Registry and Patient Reported Outcomes via the 
online pariticipant portal.  Additionally, p articipant engagement will include:  
 creating a study -wide Healthcare Worker Advisory Group;  
 developi[INVESTIGATOR_88488] -centered appro aches that recognize the needs and preferences of 
healthcare workers  locally and nationally ; and 
 multifaceted approaches that combine engagement tool s, leverage the participant portal , 
use of social media , and representative healthcare worker associations or leaders . 
5.3.3.  Participant Randomization  Process  
Randomization will be stratified by [CONTACT_436929]. Randomization will be monitored 
closely and the HERO registry for pre -screening will be used to ensure inclusion of key 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 21 subgroups and to ensure the tri al results are applicable to an appropriately diverse population of 
HCWs  who work in COVID -19 exposure areas. Both participants and the study team will remain 
blinded  to assignment throughout the study.  
5.4. Screen Failures  
Screen failures are defined as participant s who consent to participate in the clinical study , who 
fulfill inclusion and exclusion criteria,  but are not subsequently  randomized . A minimal set of 
screen failure information is required to ensure transparent reporting of screen failure 
participant s to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing 
requirements and to respond to queries from regulatory authorities.   
Individuals who are considered screen failures  may not be re -screened.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 22 6. Study Drug (s) 
Study  drug is defined as an y investigational drug(s), marketed product(s), or placebo intended to 
be administered to a study participant according to the study protocol.  
6.1. Hydroxychloroquine  
6.1.1.  Formulation, Appearance, Packaging, and Labeling  
Hydroxychloroquine sulfate table ts are provided as white/off -white, film -coated, round  tablet s.  
Each tablet contains 200 mg of the active ingredient (HCQ sulfate).  The non -active ingredients 
in the formulation include black ink, calcium hydrogenophosphate, carnauba wax, cornstarch , 
magnesium stearate, Opadry White YS -I-7443 and polyethylene glycol 400.  
Study drug will be packaged and labeled in a masked manner and in compliance with regulatory 
requirements.  
6.1.2.  Drug Dispensing, Storage, and Stability  
A quantity of study drug sufficient for 30-days will be provided to the participant at enrollment.   
Hydroxychloroquine should be stored at room temperature (15 °C - 30°C). 
6.1.3.  Dosing and Administration  
Participants will receive a [ADDRESS_553563] SARS -CoV. [17, 18]  Both 
chloroquine and HCQ  have been reported to have in vitro  antiviral activity against SARS -CoV -2. 
[11, 12]  In vitro  testing using Vero ce lls vary ; Yao et al demonstra ted an EC50 of 23.90 and 5.47 
uL for chloroquine at 24 and 48 hours respectively, compared to 6.14 and 0.72 for HCQ . [12] 
Liu et al reported on four multiplicities of infection (MOIs) (0.01, 0.02, 0.2, and 0.8); the 50% 
maximal ef fective concentration (EC50) for chloroquine was (2.71, 3.81, 7.14, and 7.36 μM) and 
for HCQ  was (4.51, 4.06, 17.31, and 12.96 μM). Hydroxychloroquine may exhibit higher activity 
to chloroquine in protecting Vero cells from infection (“prophylaxis”); when Vero cells were 
pre-treate d with drug before SARS -CoV -2 challenge, EC50 for c hloroquine was >100 and 18.01 
uL at 24 and 48 hours, respectively, compared to 6.25 and 5.85 for HCQ . [12] In animals, both 
drugs share similar tissue distribution patterns, with high concentrations in the liver, spleen, 
kidney, and lung reaching levels of 200 –700 times higher than those in the plasma.  [19] 
The optimal dose of HCQ  for treatment or prophylaxis is unknown. Absorption after oral dosing 
is incomplete and variable (~70 % [range: 25 to 100%]). [20] Metabolism is primarily hepatic 
with metabolites including bidesethylchloroquine, desethylhyd roxychloroquine, and 
desethylchloroquine.  [21] The drug has long half -life elimination of approximately 40 days.  [20] 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553564] dosing in other medica l conditions include: systemic lupus erythematosus  (200-400 mg 
daily given once or divided BID), malaria treatment (800 x1, followed by 400 mg at 6, 24 & 48 h 
after initial dose), Q fever (600 mg/day in 1 to 3 divided doses) and rheumatoid arthritis (200 -
400 mg daily in 1 -2 divided doses) . The recommended maximum dose  of HCQ  is 5 mg/kg 
Actual Body Weight daily.  
The dose chosen for this study is 600  mg orally BID on day 1 as a loadin g dose followed by 400  
mg QD for an additional 29 days. This dose was chosen for several reasons:  
 current in vitro  studies report a wide range of EC50 for SARS -CoV -2,  
 variability of absorption and of tissue distribution into the lung,  
 due to a lack of phase 1b data for this drug in SARS -CoV -2 infection, the optimal 
pharmacokinetic/pharmacodynamic  target is unknown.  
Yao et al made assumptions regarding the absorption and tissue distribution that were optimistic 
and recommended as an opt imal treatment dose 400  mg BID on day 1 as a loading dose followed 
by 200  mg BID daily for the remainder of the treatment course.  [12] There is concern that this 
dose will not meet the necessary pharmacokinetic/pharmacodynamic  targets for efficacy, in 
which c ase a negative study would not be due to failure of the antiviral efficacy but of 
suboptimal dosing. Yao et al also note d that the drug exposure was the same for 200  mg BID or 
400 mg QD daily dosing. We propose a higher loading dose of 600  mg BID on day 1 to ensure 
more rapid steady state tissue distribution and 400  mg QD (versus BID) dosing for ease of 
dosing and adherence.  
6.2. Placebo  
6.2.1.  Formulation, Appearance, Packaging, and Labeling  
Placebo will be provided in a similar appearance as the study drug and be pac kaged and labeled 
in a masked manner in compliance with regulatory requirements.  
6.2.2.  Drug Dispensing, Storage, and Stability  
A quantity of study drug sufficient for 30 -days will be provided to the participant at enrollment.  
Placebo  should be stored at room te mperature (15°C - 30°C).  
6.2.3.  Dosing and Administration  
All placebo doses will be oral self -administrations.  Placebo tablets will be provided in a dose 
that mimics the pi[INVESTIGATOR_436914] (HCQ).   
6.2.4.  Rationale for Selection of Dose  
N/A 
6.3. Study Drug Accountability  
Use of study drug will be tracke d via the participant portal, call center , or final in -person study 
visit. Adherence to study drug as provided will be assumed unless reported otherwise. 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553565] include the following:  
 Therapeutics that are being used in other COVID clinical trials  
 Antibiotics  
 Antifungals  
 Immunosuppressants including s teroids  
 Tylenol  
 Nonsteroidal anti -inflammatory drugs  
 Angiotensin -converting -enzyme ( ACE )/angiotensin II receptor blockers 
(ARB )/angiotensin receptor neprilysin inhibitor ( ARNI ) 
 Statin 
 HIV protease inhibitors  including lopi[INVESTIGATOR_054] , ritonavir , atazanavir, darunavir  
 ribavirin   
Prohibited m edications include those  at high risk for QT prolongation including:  
 procainamide,  
 disopyramide,  
 mexil etine,  
 flecainide,  
 propafenone.  
 amiodarone,  
 sotalol,  
 cimetidine  
 dronedarone,  
 dofetilide  
 fluoroquinolones including ciprofloxacin, levofloxacin, moxifloxacin  
 see MOP for f ull list of contraindicated medications  
6.5. Dose Modification  
This protocol allows some alteration from the currently outlined dosing schedule.   The maximal  
daily  dosing  should not exceed what is specified in the protocol.  
If moderate or severe adverse event ( AE) occurs,  that is , in the opi[INVESTIGATOR_871] , 
reasonably attributable to study intervention , then dose may be altered by [CONTACT_436930], may be temporarily  halted , or may be reduced , in consultation with the study CCC .  
Relevant reporting and discussion with the CCC  study  personnel, must  take place  prior to  dose 
modification . 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 25 If the same SAE occurs consistently across participants , then dose  or frequency of dosing may be 
reduced  by [CONTACT_436931] .  
6.6. Intervention  After the End of the Study  
No additional study drug will be provided to the participant following completion of the study.   
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 26 7. Participant Withdrawal /Termination and Study Termination  
7.1. Participant Withdrawal/Termination  
Participants will be followed until participant closeout, withdrawal of consent, or death.  
A participant may withdraw from the study at any time at his/her own request, or may be 
withdrawn at any time at the discretion of the investi gator for safety, behavioral, compliance, or 
administrative reasons. This is expected to be uncommon.  
Those who request withdraw al from the study will be asked to continue on study follow -up with 
limited participation through the Final Visit ( Section 8.1.3 ).  Limited participation may include a 
call at 30 days and 60 days to assess safety.  
If the participant withdraws consent for disclosure of future information, the sponsor may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, he/she may request destruction of any samples taken 
and not tested, and the investigator must document this in the sit e study records.  
7.2. Premature Termination or Suspension of the Study  
The study  may be temporarily suspend ed or prematurely terminated if there is sufficient 
reasonable cause. Written notification will be provided documenting reason for study suspension 
or ter mination to the investigators, funding agency, and regulatory authorities , as appropriate . 
Circumstances that may warrant termination or suspension include, but are not limited to:  
 Determination of unexpected, significant, or unacceptable risk to participa nts 
 Insufficient compliance to protocol requirements  
 Data that are not sufficiently complete and/or evaluable  
 Determination of futility after a sufficient time has passed for accrual of the primary and 
secondary outcomes  
 Recommendation by [CONTACT_4318]  
7.3. Lost to Follow -up 
Participants will be asked for proxy contacts to assess vital status and/or other clinical events if a 
participant repeatedly fails to return for scheduled visits or does not participant in remote visits.  
A participant  will be considered lost to  follow -up if he or she repeatedly fails to return for 
scheduled visits  or does not participate in remote visits  and neither the participant nor his or her 
proxy can be contact[CONTACT_9298].  
The following actions must be taken if a participant  fails to return to the clinic  or participate in 
remote visits as required by [CONTACT_1758] : 
 The site must attempt to contact [CONTACT_47995] m issed visit as soon 
as possible and counsel the participant  on the importance of maintaining the assigned 
visit schedule.  
 The site or call center will contact [CONTACT_2299]’s proxy to assess vital status or other 
clinical or safety events.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 27  Before a  participant  is deemed lost to f ollow -up, the investigator or des ignee must make 
every effort to regain contact [CONTACT_6635]  (where possible, three  telephone calls 
and, if necessary , a certified letter to the participant ’s last known mailing address or 
local equivalent methods). These contact [CONTACT_21457] ’s medical record .  If safe, and appropriate, participants who fail to respond 
to study contact [CONTACT_436932].  
 Should the participant  contin ue to be unreachable, he/she will be considered lost to 
follow -up.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553566] to follow -up, perma nent cessation of study 
drug, study drug dose modifications, or change in vital status. Data is being collected directly 
from participant a nd supported by [CONTACT_30219],  as needed.  
8.1. Schedule of Events   
 
Table 1: Schedule of Events  
                                                 
 
 
 
1 Participant’s medical record may be reviewed to confirm SAEs and Events of Special Interest (EOSIs).   
 
 
 
 
 
 
 
Procedures 
Baseline : Onsite  
(Day 0)  
Follow -up: Remote  
 (Day 7 ± 2 days ) 
Follow -up: Remote   
(Day 14 ± 2 days ) 
Follow -up: 
Remote  (Day 
21 ± 2 days ) 
  Follow -up: 
Onsite  (Day 
30 + 5 days ) 
Final Visit : 
Remote  (Day 
60 + 5 days ) 
Healthcare Worker Clinical  Trial        
Consent  X      
Demographic Information  X      
Eligibility criteria confirmed  X      
Randomization  X      
Receipt of s tudy drug  or placebo  X      
Continued use study drug   Continuous   
Clinical Assessments      
  
  
 Abbreviated medical history  X      
Concomitant Meds of Interest  X  X  X X 
Temperature  X      
COVID -19 Questionnaire   X X X X X 
QoL Questionnaires  X  X  X X 
SAEs and Events of Special Interest1  Continuous via participant portal and at Onsite 
Visits  
Biospecimen Collection        
Nasopharyngeal swab for COVID -19 X    X  
Blood collection for exploratory analysis  X    X  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 29 8.1.1.  Baseline  (On-site, Day 0 ) 
The following events will occur at the Baseline study visit:  
 Consent : The consent process should be done in accordance with local IRB requirements.  
Phone consenting may be facilitated through the e -consent process via the online portal.  
 Demographic information will be collected including , but not limited to,  age, sex, race,  
ethnicity , and  occupation  
 Eligibility criteria confirmation  
 Randomization : Participants must be randomized within 3 days of consent, which can be 
done in -person or by [CONTACT_648].    
 Participan t will receive 30-day supply of study drug  or placebo  
 Abbreviated medical history including smoking status, pre -existing underlying lung 
disease, underlying immunosuppression (transplant, malignancy, HIV, autoimmune 
disease) , medical conditions that may increase risk of COVID -19 infections or 
complications (diabetes, cardiovascular diseas e)  
 Concomitant medications of i nterest (Section 6.4) 
 Temperature  
 QoL questionnaires  
 Nasopharyngeal swab for COVID -19 diagnosis  
 Blood collection for exploratory analysis  
8.1.2.  Follow -Up 
The following events will occur at the Follow -Up study visits:  
Follow -up (Day 7 ± 2 days  – Remote) : 
 COVID -19 Questionnaire  
 Serious Adverse Event and EOSI collection  
Follow -up (Day 14 ± 2 days  – Remote):  
 Concomitant medications of interest (Section 6.4) 
 COVID -19 Questionnaire  
 QoL questionnaires  
 Serious Adverse Event  and EOSI  collection  
Follow -up (Day 21 ± 2 days  – Remote) : 
 COVID -19 Questionnaire  
 Serious Adverse Event  and EOSI  collection  
Follow -up (Day 30 + 5 days  – Onsite ): 
 Concomitant medications of interest (Section 6.4) 
 COVID -19 Questionnaire  
 QoL questionnaires  
 Serious Adverse Event  and EOSI  collection  
 Nasopharyngeal swab for COVID -19 diagnosis  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 30  Blood collection for exploratory analysis  
8.1.3.  Final Visit  (Day 60 + 5 days  - Remote)  
The following events will occur at the Final Visit:  
 Concomitant medications of interest (Section 6.4) 
 COVID -19 Questionnaire  
 QoL questionnaires  
 Serio us Adverse Event  and EOSI  collection  
8.2. Clinical  Assessments  
Temperature : temperature will be assessed  
Nasopharyngeal swab for COVID -19:   Nasopharyngeal swabs are commonly used for the 
detection of respi[INVESTIGATOR_436915] , influenza virus and 
coronavirus.  A swab is inserted into the nostril  and advanced along the floor of the nose until the 
posterior nasopharynx has been reached  and gently rotated several times to collect sufficient 
specimen for testing .  
The reference lab will notify sites of positive COVID -[ADDRESS_553567] results.  The 
notification process will occur per local guidance and will not be tracked or documented  by [CONTACT_58860].  
8.3. Quality of Life and COVID Questionnaires  
COVID -19 Questionnaire  
The following QoL questionnaires will be used in this study:  
 PROMIS Emotional Distress – Anxiety – Short Form : Patient -Reported Outcomes 
Measurement Information System (PRO MIS) measures were developed through a 
collaborative process funded by [CONTACT_7681] (NIH).  [22] Anxiety has 
been i dentified by [CONTACT_436933] a key domain of mental health 
and was defined as “autonomic arousal and experience of threat”,  [23] which may 
compound the effects of stress in healthcare providers.  [24] The PROMIS E motional 
Distress – Anxiety -Short Form  [25] has previously been shown to reliably assess anxiety 
in a variety of clinical populations.  [26-28] The Anxiety short form consists of eight  
items each rated  from 1 -5 points (1=never and 5= always), with higher scores indicating 
greater anxiety.   
 Single -item burnout measure : Prior work has demonstrated that burnout among medical 
professionals may adversely affect  patient care. The current standard for burnout 
assessment is the Maslach Burnout Inventory (MBI), however, the full MBI consists of 
22 items and may be burdensome to complete. Across previous studies, one emotional 
exhaustion (EE) question (“I feel burned out from my work”, rated on a 7 -point Likert 
scale ranging from “Never” to “Daily”, with higher scores indicating more burnout) has 
exhibited hig h factor loading within its respective domain (MBI -EE). [29-32] A non -
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 31 proprietary adaptation of this item  [33] has shown good performance relative to the full 
MBI in prior studies of medical students and physicians.  [34, 35]      
 Patient Health Questionnaire ( PHQ -2): The Patient Health Questionnaire (PHQ -9) is a 9 -
item tool commonly used to assess depression severity. Given the need for a briefer 
measure to screen for depression in bus y settings, a 2 -item version of the depression 
module has been developed and validated.  [36] The abbreviated scale, known as the 
PHQ -2, consists of questions about two domains: frequency of depressed mood and 
anhedonia, e ach scored from zero (not at all) to three  (every day), with higher scores 
indicating greater depression severity. The measure has demonstrated good performance 
in diverse clinical [37-40] and healthcare provider populations.  [41-44]  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553568] of a clinical trial. An AE can therefore be a ny change in clinical 
status, ECGs, routine labs, x -rays, physical examinations, etc., that is considered clinically 
significant by [CONTACT_1704] .  
A SAE or serious suspected adverse reaction or serious adverse reaction  as determined by [CONTACT_436934]:  
 Death  
 Life-threatening AE (“life -threatening” means that the study participant was, in the 
opi[INVESTIGATOR_26335], at immediate risk of death from the reaction as it 
occurred and required immediate intervention)  
 Persistent or s ignificant incapacity or substantial disruption of the ability to conduct 
normal life functions  
 Inpatient hospi[INVESTIGATOR_1081]  
 Congenital abnormality or birth defect  
 Important medical event that may not result in o ne of the above outcomes, but may 
jeopardize the health of the study participant or require medical or surgical intervention 
to prevent one of the outcomes listed in the above definition of serious event  
Hospi[INVESTIGATOR_5187] a preexist ing condition that did not worsen from 
baseline does not meet the definition of an SAE. Hospi[INVESTIGATOR_31561] a stay in the 
hospi[INVESTIGATOR_88489] 24 hours.  
An unexpected adverse event  is defined as any adverse event, the specificity or severity of wh ich 
is not con sistent with the package insert . 
9.1.1.  Collecti on Period for  AE and SAE Information  
Study participants (and their designated emergency proxies) will be instructed to report Events of 
Special Interest (EOSI) and SAEs  through their access t o the study’s participant portal .  Events 
of special interest and SAEs  will also be elicited during each remote follow -up visit  and during 
the Baseline and Day [ADDRESS_553569] access to AE reporting via the 
electronic portal from the signing of the informed consent form (ICF)  until the Final Visit  (Day 
60).  
Medical occurrences that begin before the start of study intervention but after obtaining informed 
consent will not be considered an AE. 
Non-serious AEs will not be collected unless the event meets the criteria of an EOSI .  
Events of Special Interes t will be collected from the start of study drug until Final Visit or until 
[ADDRESS_553570] dose if participant early terminates the study.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 33 9.1.2.  Assessing Causality of a Suspected  Unexpected Serious Adverse Reaction  
(S[LOCATION_003]R)  
If a S[LOCATION_003]R  occurs, t he investigator/delegate will assess the relationship to study drug by [CONTACT_436935]:  
 Related: The event has a relationship to study drug.  
 Not related: The event has no temporal relationship to study drug or the AE has a much 
more likely alternate etiology or due to an underlying or concurrent illness or effect of 
another drug.  
9.1.3.  Reporting and Monitoring of SAEs  
Although HCQ is approved for marketing in the [LOCATION_002], its investigational use for 
prevention of COVID -[ADDRESS_553571], and 
Unanticipated Problems that are  reported will be compi[INVESTIGATOR_436916]. There 
will be  no expedited reporting of individual SAEs  as safety reports per 21 CFR 
312.32(c)(1)(i)(A) or 21 CFR 312.32(c)(1)(i)(B) . The DSMB chair will review SAEs weekly, 
and the convened  DSMB will perform aggregate reviews  of SAEs every two weeks. The 
convened DSMB  will be responsible for determining if the safety reporting criteria are met per 
21 CFR 312.32(c)(1)(i)(C)  and 21 CFR 312.32(c)(1)(iv)  so that the IND sponsor and study team 
remain blinded . The  DSMB  will prepare an aggregate report for submission to the FDA if the 
DSMB determines that an SAE occurs markedly more frequen tly in the drug treatment group 
than in the control group . An aggregate safety report will be submitted  to FDA  as soon as 
possible, but in no case later than [ADDRESS_553572] from the Agency following the submission of any aggregate reports.  
Individual S[LOCATION_003]Rs will be reported b y the DSMB as expedited events to the FDA; [ADDRESS_553573] and should be recorded even if they  do 
not meet the criteria above as Serious Adverse Events . 
The following are EOSI  that are possibly related to the use of HCQ:  
 Arrhythmias  (ventricular)  
 Hepatic Failure  
 Bone marrow failure  
 Aplastic anemia  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 34  Prolonged QT interval  
 Angioedema  
 Dermatitis exfolia tive  
 Acute generalized exanthematous pustulosis (AGEP)  
 Psychosis  
 Suicidal Ideation  
 Seizure  
 Methemoglobinemia  
 
The following are also considered Events of Interest to the study:  
 Fevers  
 Sepsis  
 Acute renal failure  
 Disseminated Intravascular Coagulation (DIC)  
 Secondary bacterial infection  
The following are treatments or interventions associated with an event that will be collected:  
 Supplemental oxygen use  
 Non-invasive ventilation including BiPAP/CPAP  
 Pressors  
 Mechanical ventilation/intubation  
 Intensive C are Unit (ICU) admission  
 Extracorporeal Membrane Oxygenation (ECMO)  
9.2. Unanticipated Problem (UP) and Terminations  
9.2.1.  Definition of Unanticipated Problem   
The Office for Human Research Protections (OHRP) considers unanticipated problems involving 
risks to participants or others to include, in general, any incident, experience, or outcome that 
meets all of the following criteria:  
 Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol -related  documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the characteristics of the participant 
population being studied.  
 Related or possibly related to participation in the research (“possibly related” means there 
is a reasonable possibility that the incident, experience, or outcome may have been 
caused by [CONTACT_3459]).  
 Suggests that the research places participants or others at a greater risk of harm (including 
physical, psychological, econo mic, or social harm) than was previously known or 
recognized.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 35 9.2.2.  Reporting of an Unanticipated Problem   
The site investigator will report UPs for their participants to the Data Coordinating Center 
(DCC ). The site may also be required to inform their reviewing  IRB about an UP occurring at the 
local institution. The UP report to the DCC will include the following:  
 A detailed description of the event, incident, experience, or outcome  
 An explanation of the basis for determining that the event, incident, experienc e, or 
outcome represents an UP  
 A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP  
 The Coordinating Center will document and review all UPs.  Details of the UP reporting 
proce ss will be located in the MOP.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 36 10. Statistical Considerations  
10.1. Statistical Hypotheses  
10.1.1.  Primary Hypothesis  
 Allocation to HCQ results in prevention of COVID -19 infection among HCWs  at risk for 
COVID -19 infection.  
10.1.2.  Secondary Hypotheses  
 Allocation to HCQ results in p revention of viral shedding of SARS -CoV -2 among HCWs  
at risk for COVID -19 infection.  
 Hydroxychloroquine administration will be safe and well tolerated . 
10.2. Sample Size Determination  
The sample size of approximately 2,[ADDRESS_553574] been considered in developi[INVESTIGATOR_436917] -HCQ  study.  
Based on several recent randomized clinical trials  studying HCQ  for inpatient COVID -19 disease 
conditions , a reduction in the clinical infection risk by a rela tive 50% is considered a clinically 
important treatment effect.  For the primary outcome of clinical infection of COVID -19, the  
sample size will provide 80% power to detect a 50% relative  decrease in the risk for the 
intervention group compared to usual care assuming that the placebo group  risk is 5%.  
Similarly, the proposed sample size w ill provide 80%  power to detect a difference of 6.5%  
(active)  vs. 10%  (placebo) . These calculations assume a two -sided Type I error rate of 0.05 with 
1:[ADDRESS_553575].  
10.3. Randomization  
HERO -HCQ  is a multi -center, double blind , randomized, parallel group, superiority study. 
Randomization will occur at the level of the individual participant. Eligible participants will be 
randomized via the study website in a 1:1 ratio to either HCQ  or matching placebo. 
Randomization will be stratified by [CONTACT_436936] a permuted block design with random 
block sizes . [45]   
10.4. Blinding  
The HERO -HCQ Steering Committee along with site investigators , PCORI Program Staff , and 
study participants will remain blinded until database lock.  Limited staff will be unblinded to 
handle randomization codes, deliver the interventions to sites, and prepare DSMB reports. The 
statistical staff responsible for preparing DSMB reports will  not directly interact with the clinical 
team that delivers care to the study participants.  
The Interactive Voice Response System /Interactive Web Response System will be programmed 
with blind -breaking instructions. Participant safety must always be the fir st consideration in 
making an unblinding determination. If the investigator decides that unblinding is warranted, the 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553576] the Coordinating Center for unblinding a participant’s intervention 
assignment .  
10.5. Populations for Analyses  
The primary analyse s will includ e all randomized participants  with a baseline negative RT -PCR 
test.  
Analyses of safety and clinical events will be based on the population of all randomized 
participants.  
10.6. Statistical Analyses  
The statistical analysis plan will be finalized prior to  database lock  and it will include a more 
technical and detailed description of the statistical analyses outlined  in this section. This section 
is a summary of the planned statistical analyses of the most important endpoints including 
prima ry and key secondary endpoints.  
10.6.1.  General Considerations  
Statistical comparisons will be performed using two -sided significance tes ts. Baseline 
demographic and clinical variables will be summarized for each randomized arm of the study. 
Descriptive summaries of the distribution of continuous variables will be presented in terms of 
percentiles (e.g., median, 25th and 75th percentiles) a long with means and standard deviations.  
Categorical variables will be summarized in terms of frequencies and percentages.  
The primary endpoint is  clinical infection with COVID -19.  Individual participants are expected 
to receive study drug for 30 days an d will be followed for another 30 days for clinical events and 
patient -reported outcomes . Data collected during the 60-day follow -up will be included in the 
primary analyses.  
Participants that develop symptoms of COVID -19 will follow local clinical and/or employee 
health protocols for testing and management.  If testing is done per protocol, the results will be 
used for confirmation of the primary outcome.  However, in some regions, testing may not be 
done for individuals with suspected COVID -[ADDRESS_553577] the different approaches expected for testing and management of healthcare 
workers who develop symptoms of C OVID -19, the primary outcome includes both confirmed 
and suspected clinical COVID -19 infections .   
The primary endpoint  will be tested at the two -sided 0.05 level .  All secondary endpoints will be 
tested at the 0.05 level.   
10.6.2.  Primary Endpoint  
The primary an alysis of the primary endpoint will be based on the Fisher’s exact test.  The 
difference in proportions and the associated 95% confidence interval will be the primary measure 
used to summarize the treatment effect.   
A secondary analysis of the primary outcome of clinical infection with COVID -19 will be based 
on a logistic regression model with an indicator variable for the treatment group. The estimated 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 38 odds ratio and associated 95% confidence interval  will be used to summarize the results from 
these an alyses .   
A sensitivity analysis will use the time-to-clinical infection  with COVID -[ADDRESS_553578] function stratiﬁed by [CONTACT_3725].  [46, 47]  The estimated hazard ratio and 
associated 95% confidence interval will be used to summari ze the treatment effect.   
10.6.3.   Secondary Endpoint(s)  
For the viral shedding of SARS -CoV -[ADDRESS_553579] defined according to baseline characteristics.  These 
subgroups will be specified in the Statisti cal Analysis Plan.  The planned sub -groups will include 
age, sex, race/ethnicity, occupation, and COVID -19 risk factors . 
For each subgroup analysis, a logistic regression model (or linear model) will be used that is 
similar to the one described above, but with additional terms identifying subgroup membership 
and the intervention by [CONTACT_226418].   
10.6.6.  Adherence and Retention Analysis  
Treatment dropouts and consent withdrawals will be tracked by [CONTACT_436937] -
up assessment .  Participant s will be asked about their use of stu dy drug during telephone follow -
up.  Those reporting discontinuation or switching will be asked about the reasons for 
discontinuation /switching .   
Because study participants are HCWs, it is expected that this study wil l have excellent retention.  
Measures of study retention to inform follow -up time wi ll be based on a number of measures, 
weekly we b-based check -ins for symptoms and  exposure history  or in-person visit.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553580] ed to ensure the safety of study participants and evaluate 
the accumulating endpoint data by [CONTACT_1570].  Regular DSMB meetings will m onitor  the 
following parameters at a minim um: 
 Recruitment progress  
 Enrollment overall and by [CONTACT_12125]  
 Adherence, ret ention, and status of data collection  
 Events of special interest  
 Unanticipated problems  
 Serious adverse events  (SAEs)  
Interim examination of clinical endpoints will be based on the accrual of primary endpoint data.   
It is expected that reviews of the data will occur approximately weekly following the enrollment 
of the first participants.  
For ethical reasons, interim examinations of key safety and process data will be performed at 
regular intervals during the course of  the trial.  The DCC  will create reports to track pa rticipan t 
enrollment, rates of adherence with the assigned treatment strategy, and frequency of protocol 
violations.  Prior to each meeting, the DCC  will conduct any requested statistical analyses and 
prepare a summary report along with the following information: pa rticipant enrollment reports, 
rates of adherence with the assigned treatment, and description of SAEs.  
Safety reports will be prepared for the DSMB approximately weekly once enrollment begins.  
For futility monitoring, HERO -HCQ will employ a flexible approach based on the prediction 
interval methods  of Evans, Li, and Wei. [48]  These flexible methods allow for the assess ment of 
treatment differences as well as the precision related to those estimates.  The futility reviews may  
include predicted interval plots as a tool to summarize the information.   To implement these 
methods, we will predict the confidence intervals at t he end of the study conditional on a range 
of reasonable assumptions including the null hypothesis, the alternative hypothesis, and the 
observed trend.  The upper and lower limits of these prediction intervals will be compared with 
‘acceptable’ treatment g roup differences that allow for the incorporation of other information 
including the safety profile of the intervention.   It is expected that the first futility assessment 
will occur once the first [ADDRESS_553581] .  
The method of Haybittle and Peto will be proposed as the primary guide for interpreting inter im 
efficacy analyses . [49, 50]   The four interim efficacy analyses are expected to occur after the first 
1000, [ADDRESS_553582] completed their 30-day visits .  The proposed 
efficacy monitoring guideline uses large critical values (p≤0.001) for the treatment group 
comparison of the outcome of clinical infection with COVID -19 at each  assessment until the 
planned final  analysis.  A two -sided stoppi[INVESTIGATOR_436918] -cause mortality with p<0.[ADDRESS_553583] rule for early termination.   It is expected that both internal and external factors will 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553584]  (DSMB) 
The DSMB wil l monitor participant safety and study performance.  A DSMB charter that 
outlines the operating guidelines for the committee and the procedures for the interim 
evaluations of study data will be developed by [CONTACT_436938].   Reports 
will be prepared by [CONTACT_436939], or as requested 
by [CONTACT_2020], and will include interim analyses of primary and secondary endpoints, 
additional safety events, and other information as requested by [CONTACT_436940].  After each 
scheduled closed meeting, the DSMB will send a recommendation to the IND sponsor  to 
continue, modify , or terminate  the study.  After approval, the recommendations will be 
forwarded by [CONTACT_436941] , regional and national 
IRB/Ethic Committees, as applicable. DSMB reports will be the primary mechanism for 
reporting safety concerns to FDA , as needed .  The DSMB will establish links with the FDA and 
other appropriate DSMBs as possible to ensure rapid communication of important safety findings 
as needed.   Please refer to the  DSMB Charter  for further details . 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553585] (IRB)  
The protocol, ICF(s) , recruitment materials, and all participant materi als will be submitted to the 
IRB(s)  of record  for review and approval . This approval must be obtained before any participant 
is enrolled. Any amendment to the protocol will require review and approval by [CONTACT_1201](s) 
before being implemented in the study. All changes to the consent form will also be IRB -
approved and a determination will be made regarding whether previously consented participants 
need to be re -consented.  
11.2. Informed Consent Process  
Consent forms describing in detail the study agent, study procedures, and risks are given to the 
participant and documentation of informed consent is required prior to starting study procedures. 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in 
the study and continues throughout the individual’ s study participation. Extensive discussion of 
risks and possible benefits of participation will be provided to the participants. Consent forms 
will be IRB -approved and the participant will be asked to read and review the document. The 
investigator (or the ir delegate) will explain the research study to the participant and answer any 
questions that may arise. All participants will receive a verbal explanation in terms suited to their 
comprehension of the purposes, procedures, and potential risks of the study  and of their rights as 
research participants.  Participants will have the opportunity to carefully review the written 
consent form and ask questions prior to signing.  
The participants should have the opportunity to discuss the study and think about it pri or to 
agreeing to participate. The participant will sign the informed consent document prior to any 
procedures being done specifically for the study. The participants may withdraw consent at any 
time throughout the course of the study. A copy of the inform ed consent document will be given 
to the participants for their records. The rights and welfare of the participants will be protected 
by [CONTACT_436942] e in this study.  
The study team will distinguish between the desire to discontinue study drug and the desire to 
withdraw consent for study follow -up. In the event that a participant withdraws consent, the 
investigator or his designee will clarify with the participant and document whether the 
withdrawal is a temporary or permanent, and if a full or partial withdrawal.  
11.3. Participant and Data Confidentiality  
Participant confidentiality is strictly held in trust by [CONTACT_3486], their staff, 
and the sponsor(s) and their agents. This confidentiality is extended to cover testing of biological 
samples in addition to the clinical and private information relating to participants. Therefore, the 
study protocol, documentation, data, and all other infor mation generated will be held in strict 
confidence. No information concerning the study or the data will be released to any unauthorized 
third party without prior written approval of the sponsor. The study participant’s contact 
[CONTACT_436943].  
 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553586] to biosample storage will not be possible a fter the study is 
completed; however, samples already distributed to investigators will not be recalled and data 
generated from those samples will be retained.  
11.5. Site Management and Quality Assurance  
The study team will work in tandem to ensure that the data  collected in this study are as complete 
and correct as possible. We will implement a four -step, multi -functional approach to quality 
control:  
 Training: Prior to the start of enrollment, the clinician investigators and study coordinators 
at each site will be trained with the clinical protocol and data collection procedures, 
including how to use the Electronic Data Capture (EDC) system. Follow -up training and 
training for new study personnel will be conducted as needed.  
 Monitoring: The CCC, along with the DC C, will ensure that data collection is handled 
properly, will provide in -service training, and will address questions from site investigators 
and coordinators. Review  of data quality and completeness  will occur  on a regular and 
ongoing basis.  Any issues w ill be address ed.  There will be no on -site monitoring or 
source document verification.  
 Managing data: After the data have been transferred for statistical summarization, data 
description, and data analysis, further crosschecking of the data will be perfor med with 
discrepant observations being flagged and appropriately resolved through a data query 
system.  
 Reviewing data: Events of interest will be reviewed  to ensure an appropriate standardized 
classification of the component events comprising the primary c omposite endpoint.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553587]. Participant selection facilitated by [CONTACT_436944]. Follow -up from the portal and  call center is expected to keep participants engaged and 
help them maintain their assigned treatment by [CONTACT_436945]. Minimal levels of intervention and a focus on observing rather than influencing the study 
particip ants greatly increases the likelihood that Good Clinical Practices will be followed.  
Central statistical monitoring is particularly useful for identifying unusual patterns in data. We 
will deploy an integrated approach to quality surveillance, which will be detailed in the 
appropriate study management plans.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553588] Keepi[INVESTIGATOR_007]  
12.1. Data Collection and Management Responsibilities  
The data management platform for this study is primarily focused on a single web -based portal 
that will support all data  collection and interactions with participants and study sites.  Related 
operational systems supporting the Coordinating C enter activities and services provided partners 
(e.g. lab, drug supply) will be embedded within each of those organizations and interf aced via a 
routine set of data transfers or application interfaces.  The figure below ( Figure 1) illustrates the 
systems and interactions required to en able a well -coordinated study delivery plan.  Study 
participants accessing the system directly and the emphasis on self -reported data does require 
primary identifiers to be maintained within a limited number of systems.  These data will be 
secured such tha t it is only maintained in the minimum required systems and accessible to the 
minimum number of people to perform the study procedures described in this protocol.  The 
primary method of identifying a participant will be with a unique participant identifica tion 
number.  
 
Figure 1: Data Flow Diagram  
Participants will use a study portal developed by [CONTACT_436946], data reporting and 
scheduling activities in this study.  The Verily system leverages the Google infrastructure, 
including hosting, security, user account management and the study -specific data system.  
Leveraging this infrastructure ensures very high levels of system security and support are 
embedded in the portal.  Although leveraging Google infrastructure this is a stand -alone portal 
Almac
Clinical 
Supply 
Packaging & 
Distribution
Integrated Study Data 
Repository
[automated receipt , integration , reconciliation , 
transactional exchanges , QC]
(Informatica , Oracle )
Trial 
Payment 
System
Consent , Self-report  & trial data
 Trial System
Analysis and Dataset Creation , 
Reporting
[Transfomation , Registry /Trial dataset generation , 
visual analytics & reporting , aggregate quality 
reviews , protocol compliance checks , etc]
(SAS, SAS VA , R, etc.)
Registry 
System
CTMS
(Siebel )
DCRI System
Study Data Platform
Vendor / Sub
Site
 Participant
Central Lab
Call Center 
Comms 
Center Db
(Model Db )
DSMB 
Meetings
Green = for required for 
registry
Verily
Baseline Platform 
PHI PHIPHI
Blinding data
Coding
(IBM CD )

CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 45 and no data is shared from other sources with the  study, and no study data will be shared with 
any other Google systems.   
The study systems at the DCRI D CC support the orchestration of work across partners/vendors, 
integration of study data for operational reporting and statistical analysis, and busines s processes 
like tracking regulatory documents and processing site payments. All systems are 21CFR11 
compliant and adhere to the Duke Information Security Office policies. All external data 
transfers are exchanged via SSH File Transfer Protocol ( SFTP ) or encrypted application 
programming interface ( API) directly between systems.  
The call c enter staff will contact [CONTACT_436947], as described in the study consent 
form, to obtain precious follow -up information should a participant not respond directly within 
the portal.  The participant contact [CONTACT_436948] u sed by [CONTACT_436949] c enter for these contacts.  This system manages call 
queues , scheduling, and call processing information.  The study data obtained by [CONTACT_436950].   
The study data is managed using a set of tools including Oracle (relational database management 
system), Informatica (data exchange/extract -transform -load procedur es), Cognos (operational 
reporting), SAS , and SAS Visual Analytics (statistics).   
Data quality is managed at each stage of its lifecycle. Data collected in the portal conforms at 
inception to highly structured data elements and protocol -specific rules, su bsequent data transfers 
are checked to conform to format and semantic specifications and all data is assessed for 
referential integrity across sources through a set of reconciliation practices upon integration then 
followed by a variety of logical checks w ithin a participant and in aggregate.  
12.2. Study Records Retention  
Study documents should be  retained for a minimum of six  years after the study has ended. 
However, if required by [CONTACT_427], these documents should be retained for a longer 
period. No re cords will be destroyed without the written consent of the sponsor, if applicable. It 
is the responsibility of the sponsor to inform the investigator when these documents no longer 
need to be retained.  
12.3. Protocol Deviations  
A protocol deviation is defined as  non-compliance with the  clinical study  protocol, GCP, or 
MOP requirements. The  non-compliance may be on the part of the partici pant, site investigator, 
or the si te staff.  
A major  protocol deviation is a significant divergence from the protocol that may have 
significant effect on the subject’ s safety, rights, or welfare and/or on the integrity of the study 
data.  Major protocol deviations  must be sent to the study  IRB and l ocal IRB per their guidelines, 
recorded in s ource documents, and r eported to the coordinating center . Major protocol deviations 
will be tracked . 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 46 12.4. Publication and Data Sharing Policy  
This study will comply with the PCORI Public  Access Policy, which  ensures that the public has 
access to the results of PCORI -funded res earch. Methods of data sharing for HERO -HCQ  will 
include 1) archiving de -identified data in a data repository and 2) sharing of limited datasets 
under a Data Use Agreement (DUA) and IRB approval. Data will be made available to qualified 
investigators by [CONTACT_88563] a fully de -identified dataset in  a platform to be determined at the end 
of the trial . Both repositories allow users to search, view study information, and then submit an 
application to receive data. Prior to archiving study data, the DCC will produce a final dataset 
that will be stripped  of all personal health information (PHI), including full date elements, in 
compliance  with the Health Insurance Portability and Accountability Act (HIPAA) privacy rule. 
The relative timing of an event will be retained in the dataset converting t o study days instead of 
dates.  
The study result will be returned , including some participant specific results, to enhance value from 
participation.  Study results will be  disseminate d to the public and the medical community through 
presentations at scient ific meetings and publishing manuscripts in high impact peer -reviewed 
journals. The International Committee of Medical Journal Editors (IC MJE) member journals have  
adopted a cli nical studies  registration policy as a condition for publication. The ICMJE defines a 
clinical study as  any research project that prosp ectively assigns human participants  to 
intervention or concurrent comparison or control groups to study the cause-and-effect 
relationship between a medical intervention and a health outcome. The ICMJE  policy, and  the 
Section [ADDRESS_553589] of 2007, requires that all 
clinical studies be regi stered in  a public registry such as ClinicalTrials .gov, which is spons ored 
by [CONTACT_88564]. For interventional cli nical trials per formed under NIH IC 
grants and cooperative agreements, it is the gra ntee’s responsibility to register the study in an  
acceptable registry, so the research results  may be considered f or publicati on in ICMJE  member 
journals.  
 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553590], interpretation and 
dissemination of the trial.    
The Executive Committee is a subset of the Steering Committee and consists of the Principal 
Investigators of the Clinical Coordinating Center ( CCC ), the DCC,  and the Steering Co mmittee 
Co-Chai r. The Executive Committee is charged with overseeing the day -to-day operations of the 
trial as an extension of the Steering Committee, to ensure efficient and high -quality performance.  
The Coordinating Center is composed of a CCC  and a DCC , each overseen by [CONTACT_168062](s).  The CCC  is responsible for study coordination, site management, 
communication, and financial administration.  The DCC  is responsible for treatment allocations, 
receipt and processing of data, quality control p rograms, and statistical analysis and reporting.   
An independent DSMB  will oversee the safety and welfare of trial participants as well as provide 
recommendations for continuation, discontinuation or revision of the trial.  
 
 
 
Figure 2: Operational Structure Diagram  

CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 48 14. Summary of Changes  
Protocol Version (version #, date)  Summary of Changes  
Version 0.2, 4/07/2020  Changed all study dates from weeks to days; 
updated Key Exclusion Criteria in the 
synopsis to be consistent with the Exclusion 
Criteria in the eligibility section (Section 5.2); 
updated schema to correct events that will 
occur in HERO Registry vs. HERO -HCQ 
Clinical trial (Section 1.2); clarified that all 
Eligibility Criteria will be obtained per 
participant (Section 5); modified in clusion 
criteria to allow HCWs in “related healthcare 
services” and those who work in a COVID -19 
testing location or inpatient hospi[INVESTIGATOR_5120]/area 
with potential COVID -19 cases (Section 5.1); 
added cirrhosis as an Exclusion Criteria 
(Section 5.2); clarified that participant 
recruitment will be exclusively from the 
HERO Registry (S ection 5.3.1 ); clarified that 
participants may be called at 30 and 60 days 
for follow -up after early withdrawal (Section 
7.1); added that participants may be contact[CONTACT_436951] -up (Section 7.3); added 
windows to St udy Visits (Section 8.1); added 
“Serious” to the AE collection line and a 
footnote to details medical record review at 
Final Visit for SAEs and Events of Special 
Interest ( Table 1); added language that 
positive COVID -[ADDRESS_553591] results be 
communicated to sites and they are expected 
to report to the participant and state health 
department per local regulations (Section 
8.2); provided more details about safety 
reporting to FDA (Section 9.1.3 ); removed 
specified document requirements for 
unblinding (Section 10.4); participants with 
suspected COVID -19 will be included in the 
primary outcome (Section 10.6.1 ); updated 
Interim Analysis Plan (Section 10.7); 
specified that the DSMB will send study 
recommendation s to the IND sponsor only 
(Section 10.8); clarified that blood samples 
will be sent to a central lab (Section 11.4); 
updated the Data Flow Diagram to reflect 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 49 changes in data flow ( Figure 1); clarified that 
PCORI is the funding agency (Section 13); 
removed PCORI from the Operational 
Structu re Diagram ( Figure 2). 
Version 1.0, 4/10/2020  Changed Randomization Section under Study 
Population to Participation Randomization 
Process sub -heading (Section 5.3.3 ) to avoid 
confusion with Randomization section in the 
Statistical Section (Section 10.3); corrected 
HCQ table shape from peanut -shaped to 
round (Section 6.1.1 ); added the following 
exclusio n criteria per FDA recommendation 
(Section 5.2): history of severe skin reactions, 
history of psoriasis or porphyria, ventricular 
arrhythmias requiring medical treat ment, 
severe coronary artery disease or heart 
failure/cardiomyopathy with ongoing 
symptoms, known cirrhosis or severe liver 
disease,  current or planned use of anti -seizure  
drugs, history of Glucose -6-phosphate 
dehydrogenase deficiency; adding 
hypoglycemia and neuropsychiatric events as 
risks of taking HCQ (Section 2.3.1 ); updated 
the primary analysis population to include 
only randomized participants  with a baseline 
negative RT -PCR test per FDA 
recommendation (Section 10.5); removed ITT 
population analysis (Sections 10.5 and 
10.6.1 ); added all -cause mortality analysis 
(Section 10.6.3 ); changed proportional 
hazards to logistic regression (Section 10.6.5 ). 
Version 2 .0, 5/01/2020  Updated Key Inclusion and Exclusion Criteria 
in the Synopsis (Section 1); numbered 
eligibility criteria (Sections 5.1 and 5.2); 
added the following to Inclusion Criteria: 
broadened definition of HCW  and removed 
“able to speak and read English or Spanish”  
(Section 5.1); added the following Exclusion 
Criteria: c urrent or planned use of HCQ 
(study drug) for any indication  and removed 
HCQ from the subsequent bullet due to 
redundancy with the added criteria (Section 
5.2); updated participant recruitment and 
engagement s trateg ies (Section s 5.3.1  and 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 50 5.3.2 ); COVID -19 questionnaire and AE 
collection removed at baseline ( Table 1 and 
Section 8.1.1 ); clarified that data may be 
collected from participant’s medical record 
(Section 8 and Table 1); sites should notify 
CC of HCW dose modifications (Section 8); 
added that randomization should occur within 
3 days of consent and may be done in -person 
or by [CONTACT_648] (Section 8.1.1 ); AE collection 
changed to SAE and EOSI collection as only 
SAEs and EOSIs will be collection (Sections 
8.1.1 , 8.1.2 , and 8.1.3 ); added S[LOCATION_003]R 
causality and expedited reporting of S[LOCATION_003]Rs 
to FDA (Section 9); corrected Quality 
Insurance to Quality Assurance (Section 
11.5); other administrative changes . 
Version 3.0, 7/07/2020  Updated Study Rationale and Background 
(Sections 1.2, 2.1, 2.2).  Changed the 
definition of confirmed and suspected clinical 
infection with COVID -19 for the primary 
endpoints (Section 3).  The rationale for this  
update is as follows: Initial reports of COVID 
like illness  identified fever as the most 
common symptom, reported as occurring in 
>80% of cases; thus, in an attempt to increase 
the specificity of the definition for suspected 
clinical infection , the originally primary 
endpoint require d 2 symptoms of fever plus 
either cough or dyspnea. Data from a recent 
publication  [51] resulted in calculations that 
showed only 40% of lab confirmed cases 
reported fever, 30% reported fever plus cough 
and only 10% reported fever plus shortness of 
breath. Similarly, only 38% of probably cases 
reported fever,  25% reported f ever plus 
cough and only 8% reported fever plus 
shortness of breath. This  data indicates that 
the more stringent definition of suspected 
COVID infection would underestimate actual  
case rate. Thus the endpoint is being amended 
to redefine suspected clinical  COVID 
infection as only one of three new -onset 
symptoms (fever or cough or dyspnea).  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 51 Updated sample size (Section s 1.1, 1.2, 4.1 
and 10.2), updated the statistical analysis plan 
for the primary objective and the interim 
analysis ( Sections 1.1, 10.6.1 , 10.6.2 , 10.7), 
updated inclusion to broaden definition of 
HCW (Sections 1.1 and 5.1), clarified End of 
Study Visit as completing the Final Visit at 60 
days (Section 4.2), and other minor 
administrative changes.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 52 15. References  
1. COVID -19 Map FAQ . 2020  [cited 2020; Available from: 
https://coronavirus.jhu.edu/map -faq.html . 
2. McIntosh, K. Coronavirus disease 2019 . 2020  [cited 2020 March 24].  
3. Burton, T.a.L., P, Human Testing Begins Earlier Than Expected For U.S. Coronavirus 
Vaccine.  The Wall Street Journal, 2020.  
4. Minder, R.a.P., E, Virus Knocks Thousands of Hea lth Workers Out of Action in Europe.  
The [LOCATION_001] Times, 2020.  
5. Wang, X., X. Zhang, and J. He, Challenges to the system of reserve medical supplies for 
public health emergencies: reflections on the outbreak of the severe acute respi[INVESTIGATOR_436919] 2 (SARS -CoV-2) epi[INVESTIGATOR_436920].  Biosci Trends, 2020. 14(1): p. 
3-8. 
6. Grein, J., et al., Compassionate Use of Remdesivir for Patients with Severe Covid -19. 
New England Journal of Medicine, 2020. 382(24): p. 2327 -2336.  
7. Beigel, J.H., et al., Remd esivir for the Treatment of Covid -19 — Preliminary Report.  New 
England Journal of Medicine, 2020.  
8. McCreary, E.K., J.M. Pogue, and o.b.o.t.S.o.I.D. Pharmacists, COVID -19 Treatment: A 
Review of Early and Emerging Options.  Open Forum Infectious Diseases, 2 020. 
9. Kalil, A.C., Treating COVID -19—Off-Label Drug Use, Compassionate Use, and 
Randomized Clinical Trials During Pandemics.  JAMA, 2020.  
10. Wang, M., et al., Remdesivir and chloroquine effectively inhibit the recently emerged 
novel coronavirus (2019 -nCoV) in vitro.  Cell Research, 2020. 30(3): p. 269 -271. 
11. Liu, J., et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in 
inhibiting SARS -CoV-2 infection in vitro.  Cell Discovery, 2020. 6(1): p. 16.  
12. Yao, X., et al., In Vitro  Antiviral Activity and Projection of Optimized Dosing Design of 
Hydroxychloroquine for the Treatment of Severe Acute Respi[INVESTIGATOR_98189] 2 (SARS -CoV-2). Clin Infect Dis, 2020.  
13. Sturman, L.S., C.S. Ricard, and K.V. Holmes, Conformational ch ange of the coronavirus 
peplomer glycoprotein at pH 8.0 and 37 degrees C correlates with virus aggregation and 
virus -induced cell fusion.  J Virol, 1990. 64(6): p. 3042 -50. 
14. Zhou, D., S. -M. Dai, and Q. Tong, COVID -19: a recommendation to examine the effect 
of hydroxychloroquine in preventing infection and progression.  Journal of Antimicrobial 
Chemotherapy, 2020.  
15. Wang, D., et al., Clinical Characteristics of 138 Hospi[INVESTIGATOR_45077] 2019 Novel 
Coronavirus –Infected Pneumonia in Wuhan, China.  JAMA, 2020. 323(11): p. 1061 -
1069.  
16. Wu, C., et al., Risk Factors Associated With Acute Respi[INVESTIGATOR_97017] 2019 Pneumonia in Wuhan, China.  JAMA 
Internal Medicine, 2020.  
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 53 17. Keyaerts, E., et al., In vitro inhibition of severe acute respi[INVESTIGATOR_436921].  Biochem Biophys Res Commun, 2004. 323(1): p. 264 -8. 
18. Vincent, M.J., et al., Chloroquine is a potent inhibitor of SARS coronavirus infection and 
spread.  Virol J, 2005. 2: p. 69.  
19. Fox, R.I., Mechanism of action of hydroxychloroquine as an antirheumatic drug.  Semin 
Arthritis Rheum, 1993. 23([ADDRESS_553592] 1): p. 82 -91. 
20. Tett, S.E., Clinical pharmacokinetics of slow -acting antirheumatic drugs.  Clin 
Pharmacokinet, 1993. 25(5): p. 392 -407. 
21. McChesney, E.W., et al., Studies of the metabolism of some compounds of the 4 -amino -7-
chloroquinoline series.  J Pharmacol Exp Ther, 1966. 151(3): p. 482 -93. 
22. Cella, D., et al., The Patient -Reported Outcomes Measurement Information System  
(PROMIS): progress of an NIH Roadmap cooperative group during its first two years.  
Med Care, 2007. 45([ADDRESS_553593] 1): p. S3 -S11. 
23. The Patient Reported Outcomes Measurement Information System (PROMIS): A Walk 
Through the First Four Years, (2009).  
24. Dyrbye , L.N., et al., Association of Clinical Specialty With Symptoms of Burnout and 
Career Choice Regret Among US Resident Physicians.  JAMA, 2018. 320(11): p. 1114 -
1130.  
25. Pi[INVESTIGATOR_3708], P.A., et al., Item banks for measuring emotional distress from the Patient -
Reported Outcomes Measurement Information System (PROMIS(R)): depression, 
anxiety, and anger.  Assessment, 2011. 18(3): p. 263 -83. 
26. Batterham, P.J., et al., Psychometric Properties of 7 - and 30 -Day Versions of the 
PROMIS Emotional Distress Item Banks in an  Australian Adult Sample.  Assessment, 
2019. 26(2): p. 249 -259. 
27. Teresi, J.A., et al., Measurement Equivalence of the Patient Reported Outcomes 
Measurement Information System((R)) (PROMIS((R))) Pain Interference Short Form 
Items: Application to Ethnicall y Diverse Cancer and Palliative Care Populations.  
Psychol Test Assess Model, 2016. 58(2): p. 309 -352. 
28. Schalet, B.D., et al., Clinical validity of PROMIS Depression, Anxiety, and Anger across 
diverse clinical samples.  J Clin Epi[INVESTIGATOR_5541], 2016. 73: p. 119 -27. 
29. Maslach C, Jackson SE. The measurement of experienced burnout. J Occ Behav. 
1981;2:99 –113. 
30. Gil-Monte, P.R., Factorial validity of the Maslach Burnout Inventory (MBI -HSS) among 
Spanish professionals.  Rev Saude Publica, 2005. 39(1): p. 1 -8. 
31. Kanste, O., J. Miettunen, and H. Kyngas, Factor structure of the Maslach Burnout 
Inventory among Finnish nursing staff.  Nurs Health Sci, 2006. 8(4): p. [ADDRESS_553594], C.P., et al., Single item measures of emotional exhaustion and depersonalization 
are use ful for assessing burnout in medical professionals.  J Gen Intern Med, 2009. 
24(12): p. 1318 -21. 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 [ADDRESS_553595] the Maslach Burnout Inventory among physicians. Stress and Health. 
2004;20(2):75 –9. doi: 10.1002/smi.1002.  
34. McMurray, J.E., et al., The work lives of women physicians results from the physician 
work life study. The SGIM Career Satisfaction Study Group.  J Gen Intern Med, 2000. 
15(6): p. 372 -80. 
35. Dolan, E.D., et al., Using a single item to measure burnout in primary care staff: a 
psychometric evaluation.  J Gen Intern Med, 2015. 30(5): p. 582 -7. 
36. Kroenke, K., R.L. Spi[INVESTIGATOR_626], and J.B. Williams, The Patient Health Questionnaire -2: 
validity of a two -item depression screene r. Med Care, 2003. 41(11): p. 1284 -92. 
37. Arroll, B., et al., Validation of PHQ -2 and PHQ -9 to screen for major depression in the 
primary care population.  Ann Fam Med, 2010. 8(4): p. 348 -53. 
38. Chagas, M.H., et al., Validity of the PHQ -2 for the screening of major depression in 
Parkinson's disease: two questions and one important answer.  Aging Ment Health, 2011. 
15(7): p. 838 -43. 
39. Richardson, L.P., et al., Evaluation of the PHQ -2 as a brief screen for detecting major 
depression among adolescent s. Pediatrics, 2010. 125(5): p. e1097 -103. 
40. Corson, K., M.S. Gerrity, and S.K. Dobscha, Screening for depression and suicidality in 
a VA primary care setting: 2 items are better than 1 item.  Am J Manag Care, 2004. 10(11 
Pt 2): p. 839 -45. 
41. Unrath, M.,  et al., The mental health of primary care physicians in Rhineland -Palatinate, 
[LOCATION_013]: the prevalence of problems and identification of possible risk factors.  Dtsch 
Arztebl Int, 2012. 109(11): p. [ADDRESS_553596] Year Medical 
Students and Their Responses to a Brief Intervention. ANN BEHAV SCI MED EDUC 18, 
10–14 (2012). https://doi.org/10.1007/BF03355199 . 
43. Sen, S., et al., A prospective cohort study investigating factors associated with dep ression 
during medical internship.  Arch Gen Psychiatry, 2010. 67(6): p. 557 -65. 
44. Earle, L. and L. Kelly, Copi[INVESTIGATOR_4262], depression, and anxiety among Ontario family 
medicine residents.  Can Fam Physician, 2005. 51: p. 242 -3. 
45. Broglio, K., Randomiz ation in Clinical Trials: Permuted Blocks and Stratification.  Jama, 
2018. 319(21): p. 2223 -2224.  
46. Cox, D.R., Regression Models and Life -Tables.  Journal of the Royal Statistical Society. 
Series B (Methodological), 1972. 34(2): p. 187 -220. 
47. Glidden, D.V. and E. Vittinghoff, Modelling clustered survival data from multicentre 
clinical trials.  Stat Med, 2004. 23(3): p. 369 -88. 
48. Evans, S.R., L. Li, and L. Wei, Data Monitoring in Clinical Trials Using Prediction.  
Drug Information Journal, 2007.  41(6): p. 733 -742. 
CONFIDENTIAL  HERO -HCQ Protocol [v3.0]  
 
 55 49. Haybittle, J.L., Repeated assessment of results in clinical trials of cancer treatment.  Br J 
Radiol, 1971. 44(526): p. 793 -7. 
50. Peto, R., et al., Design and analysis of randomized clinical trials requiring prolonged 
observation of  each patient. I. Introduction and design.  Br J Cancer, 1976. 34(6): p. 585 -
612. 
51. Boulware, D.R., et al., A Randomized Trial of Hydroxychloroquine as Postexposure 
Prophylaxis for Covid -19. New England Journal of Medicine, 2020.  
 